Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two
active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).